Arthur J. Gallagher & Co. · AJG · FY2026 Q3 · Calendar Q4 2026
AJG: Q3 growth and AssuredPartners synergies support outlook
AJG’s Q3 results support a constructive operating picture: growth came from new business, retention and exposure growth, while AssuredPartners integration, M&A and productivity initiatives provide additional levers. Key tests are the durability of organic growth, synergy delivery and M&A pace.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about AJG FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management reported 18% third-quarter revenue growth, 25% net earnings growth and 5% brokerage and 10% risk-management organic growth. Brokerage margin expanded to 35.3%; AssuredPartners integration produced a 310-basis-point margin lift, and full-year 2026 guidance was maintained.
Guidance delta
Full-year 2026 guidance was maintained. Management also described an optimistic 2027 outlook, including continued organic growth and additional AssuredPartners synergies.
Key takeaways
- Organic growth was attributed to new business, client retention and exposure growth rather than rate increases.
- AssuredPartners integration is advancing, with management targeting $160 million of run-rate synergies by year-end 2026 and $325 million by early 2028.
- The company cited roughly $300 million of annualized-revenue term sheets, five Q3 tuck-in acquisitions and more than $12 billion of acquisition capacity.
Management priorities
- Complete the AssuredPartners integration, including agency-management-system rollout.
- Continue AI-driven automation, digital tools and offshore Centers of Excellence to improve productivity.
- Pursue acquisitions while expanding cross-selling and capabilities across brokerage, reinsurance, benefits and claims management.
Follow AJG with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Overweight | Overweight | Maintain | Oct 12, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Oct 7, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Oct 7, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Oct 6, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Sep 24, 2026 |
| Argus Research | Buy | Buy | Maintain | Aug 17, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 4, 2026 |
| UBS | Buy | Buy | Maintain | Aug 3, 2026 |
| Truist Securities | Hold | Hold | Maintain | Jul 31, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 31, 2026 |
| Keefe, Bruyette & Woods | Market Perform | Market Perform | Maintain | Jul 31, 2026 |
| Barclays | Overweight | Overweight | Maintain | Jul 7, 2026 |
| Jefferies | Buy | Hold | Upgrade | Jun 11, 2026 |
| BMO Capital | Outperform | Market Perform | Upgrade | Mar 24, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Dec 17, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Oct 31, 2025 |
| B of A Securities | Underperform | Underperform | Maintain | Oct 10, 2024 |
| TD Cowen | Hold | Hold | Maintain | Aug 13, 2024 |
| Raymond James | Market Perform | Strong Buy | Downgrade | Dec 12, 2023 |
| Deutsche Bank | Hold | Hold | Maintain | May 18, 2021 |
| Credit Suisse | Neutral | Outperform | Downgrade | Jan 11, 2021 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Jun 18, 2020 |
| CFRA | Hold | Hold | Maintain | May 20, 2020 |
| Keefe Bruyette & Woods | Outperform | Outperform | Maintain | Aug 1, 2016 |
| William Blair | Market Perform | Underweight | Upgrade | Mar 21, 2016 |
| Sandler O'Neill | Buy | Hold | Upgrade | Apr 10, 2014 |
| Compass Point | Buy | Neutral | Upgrade | Apr 2, 2014 |
| Macquarie | Outperform | Neutral | Upgrade | Jan 28, 2014 |
| Bank of America | Buy | Neutral | Upgrade | Jan 31, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $276.07. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Wells Fargo | Elyse Greenspan | $284 | $232.7 | +2.9% | Oct 12, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $280 | $229.85 | +1.4% | Oct 7, 2026 |
| Mizuho Securities | Analyst unavailable | $271 | $229.85 | -1.8% | Oct 7, 2026 |
| Morgan Stanley | Bob Huang | $260 | $228.91 | -5.8% | Oct 6, 2026 |
| Morgan Stanley | Analyst unavailable | $285 | $227.45 | +3.2% | Sep 25, 2026 |
| Wells Fargo | Elyse Greenspan | $291 | $229.64 | +5.4% | Sep 24, 2026 |
| Mizuho Securities | Analyst unavailable | $292 | $248.04 | +5.8% | Sep 16, 2026 |
| Morgan Stanley | Bob Huang | $290 | $248.36 | +5.0% | Aug 19, 2026 |
| Argus Research | Kevin Heal | $300 | $253.32 | +8.7% | Aug 17, 2026 |
| Morgan Stanley | Analyst unavailable | $270 | $247.3 | -2.2% | Aug 10, 2026 |
| UBS | Analyst unavailable | $299 | $249.42 | +8.3% | Aug 3, 2026 |
| Piper Sandler | Paul Newsome | $287 | $256.46 | +4.0% | Jul 31, 2026 |
| Piper Sandler | Analyst unavailable | $276 | $253.83 | -0.0% | Jul 15, 2026 |
| RBC Capital | Rowland Mayor | $300 | $256.39 | +8.7% | Jul 13, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $300 | $253 | +8.7% | Jul 9, 2026 |
| Mizuho Securities | Analyst unavailable | $287 | $256.61 | +4.0% | Jul 9, 2026 |
| UBS | Brian Meredith | $291 | $253.52 | +5.4% | Jul 8, 2026 |
| Barclays | Alex Scott | $292 | $249.77 | +5.8% | Jul 7, 2026 |
| Morgan Stanley | Bob Huang | $255 | $252.44 | -7.6% | Jul 6, 2026 |
| Jefferies | Analyst unavailable | $265 | $220.14 | -4.0% | Jun 11, 2026 |
| UBS | Analyst unavailable | $250 | $212.52 | -9.4% | Jun 8, 2026 |
| UBS | Analyst unavailable | $240 | $203.61 | -13.1% | May 21, 2026 |
| Morgan Stanley | Analyst unavailable | $265 | $202.19 | -4.0% | May 7, 2026 |
| Truist Financial | Analyst unavailable | $225 | $216.1 | -18.5% | May 1, 2026 |
| Piper Sandler | Paul Newsome | $211 | $206.4 | -23.6% | May 1, 2026 |
| Mizuho Securities | Analyst unavailable | $259 | $219.12 | -6.2% | Apr 13, 2026 |
| Piper Sandler | Analyst unavailable | $226 | $216.51 | -18.1% | Feb 23, 2026 |
| UBS | Analyst unavailable | $283 | $249.37 | +2.5% | Feb 2, 2026 |
| Truist Financial | Analyst unavailable | $271 | $250.75 | -1.8% | Jan 30, 2026 |
| Piper Sandler | Paul Newsome | $249 | $245.84 | -9.8% | Jan 30, 2026 |
| Wells Fargo | Analyst unavailable | $298 | $245.84 | +7.9% | Jan 30, 2026 |
| Mizuho Securities | Yaron Kinar | $277 | $257 | +0.3% | Jan 14, 2026 |
| Cantor Fitzgerald | Ryan Tunis | $282 | $257 | +2.1% | Jan 14, 2026 |
| Wells Fargo | Analyst unavailable | $311 | $264.84 | +12.7% | Jan 13, 2026 |
| BMO Capital | Michael Zaremski | $275 | $264.84 | -0.4% | Jan 13, 2026 |
| Barclays | Analyst unavailable | $247 | $259 | -10.5% | Jan 8, 2026 |
| Goldman Sachs | Robert Cox | $292 | $259 | +5.8% | Jan 7, 2026 |
| Piper Sandler | Analyst unavailable | $272 | $262.77 | -1.5% | Jan 7, 2026 |
| Wells Fargo | Analyst unavailable | $328 | $253.39 | +18.8% | Dec 22, 2025 |
| Morgan Stanley | Analyst unavailable | $300 | $252.64 | +8.7% | Dec 19, 2025 |
| Needham | Analyst unavailable | $272 | $251.52 | -1.5% | Dec 18, 2025 |
| UBS | Brian Meredith | $285 | $251.98 | +3.2% | Dec 17, 2025 |
| Goldman Sachs | Analyst unavailable | $293 | $252.12 | +6.1% | Dec 17, 2025 |
| Wolfe Research | Tracy Benguigui | $289 | $251.98 | +4.7% | Dec 17, 2025 |
| Evercore ISI | David Motemaden | $334 | $251.98 | +21.0% | Dec 17, 2025 |
| Truist Financial | Analyst unavailable | $280 | $251.38 | +1.4% | Dec 16, 2025 |
| Mizuho Securities | Yaron Kinar | $276 | $256.19 | -0.0% | Dec 15, 2025 |
| Piper Sandler | Analyst unavailable | $280 | $255.46 | +1.4% | Dec 15, 2025 |
| Wells Fargo | Elyse Greenspan | $344 | $245.41 | +24.6% | Dec 5, 2025 |
| Barclays | Analyst unavailable | $250 | $248.72 | -9.4% | Nov 20, 2025 |
| Piper Sandler | Paul Newsome | $295 | $246.23 | +6.9% | Oct 31, 2025 |
| Goldman Sachs | Robert Cox | $315 | $244.82 | +14.1% | Oct 31, 2025 |
| Evercore ISI | David Motemaden | $353 | $262.03 | +27.9% | Oct 31, 2025 |
| Piper Sandler | Paul Newsome | $340 | $305.84 | +23.2% | Oct 2, 2025 |
| UBS | Analyst unavailable | $329 | $297.91 | +19.2% | Sep 19, 2025 |
| Wells Fargo | Analyst unavailable | $365 | $297.91 | +32.2% | Sep 19, 2025 |
| Truist Financial | Mark Hughes | $290 | $301.82 | +5.0% | Jan 31, 2025 |
| Goldman Sachs | Robert Cox | $313 | $304.29 | +13.4% | Nov 25, 2024 |
| BMO Capital | Michael Zaremski | $325 | $281.45 | +17.7% | Nov 12, 2024 |
| Bank of America Securities | Joshua Shanker | $293 | $294.94 | +6.1% | Oct 10, 2024 |
| Jefferies | Yaron Kinar | $274 | $293.16 | -0.7% | Oct 9, 2024 |
| Goldman Sachs | Robert Cox | $300 | $279.45 | +8.7% | Sep 27, 2024 |
| RBC Capital | Scott Heleniak | $320 | $282.2 | +15.9% | Sep 20, 2024 |
| Barclays | Alex Scott | $300 | $297.75 | +8.7% | Sep 4, 2024 |
| CFRA | Catherine Seifert | $320 | $283.58 | +15.9% | Jul 26, 2024 |
| Truist Financial | Mark Hughes | $265 | $282.14 | -4.0% | Jul 26, 2024 |
| RBC Capital | Scott Heleniak | $310 | $280.9 | +12.3% | Jul 26, 2024 |
| Piper Sandler | Paul Newsome | $254 | $273.97 | -8.0% | Jul 26, 2024 |
| RBC Capital | Scott Heleniak | $290 | $254.52 | +5.0% | Jun 26, 2024 |
| Argus Research | John Staszak | $270 | $249.5 | -2.2% | May 14, 2024 |
| Piper Sandler | Paul Newsome | $252 | $234.21 | -8.7% | Apr 29, 2024 |
| Truist Financial | Mark Hughes | $255 | $244.13 | -7.6% | Apr 10, 2024 |
| Citigroup | Analyst unavailable | $228 | $196.32 | -17.4% | Feb 1, 2023 |
| Raymond James | Analyst unavailable | $215 | $190.17 | -22.1% | Dec 29, 2022 |
| Citigroup | Analyst unavailable | $225 | $193.11 | -18.5% | Dec 15, 2022 |
| Morgan Stanley | Analyst unavailable | $204 | $196.28 | -26.1% | Nov 22, 2022 |
| Jefferies | Yaron Kinar | $211 | $158.74 | -23.6% | Jun 23, 2022 |
| Raymond James | Analyst unavailable | $195 | $168.49 | -29.4% | May 2, 2022 |
| Wells Fargo | Analyst unavailable | $211 | $179.33 | -23.6% | Apr 29, 2022 |
| UBS | Weston Bloomer | $192 | $179.5 | -30.5% | Apr 20, 2022 |
| Truist Financial | Mark Hughes | $205 | $183.22 | -25.7% | Apr 11, 2022 |
| Bank of America Securities | Joshua Shanker | $151 | $166.64 | -45.3% | Oct 29, 2021 |
| Deutsche Bank | Phil Stefano | $145 | $137.99 | -47.5% | Jul 30, 2021 |
Track every rating change on AJG the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationArthur J. Gallagher & Co., alongside its various subsidiaries, operates globally, providing a wide array of services that encompass insurance brokerage, expert consulting, and outsourced claims settlement and administration. Its geographic reach extends across the United States, Australia, Bermuda, Canada, the Caribbean, New Zealand, India, and the United Kingdom. The company's business model is divided into two primary segments: Brokerage and Risk Management. The Brokerage division manages both retail and wholesale insurance operations. It also supports other brokers, including independent ones, in securing specialized or hard-to-place insurance coverage. This segment functions as a wholesale broker, managing general agent (MGA), and managing general underwriter (MGU) to distribute tailored insurance products to underwriting firms.…
Historical context
All AJG earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ERIE Erie Indemnity Company | FY2026 Q3 · Calendar Q4 2026 | +2.1% | +5.3% | Erie pairs resilient demand initiatives with thin underwriting margins |
| CBOE Cboe Global Markets, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +7.8% | Cboe pairs broad growth with new products and higher guidance |
| NWG NatWest Group plc | FY2026 Q3 · Calendar Q4 2026 | — | -9.1% | NatWest keeps guidance as deposits and wealth management expand |
| TPG TPG Inc. | FY2026 Q3 · Calendar Q4 2026 | +4.3% | +7.5% | TPG raises FRE margin outlook as capital formation accelerates |
| RKT Rocket Companies, Inc. | FY2026 Q3 · Calendar Q4 2026 | +10.8% | +5.0% | Rocket Companies: AI and servicing support resilience as Q4 outlook softens |
| EG Everest Group, Ltd. | FY2026 Q3 · Calendar Q4 2026 | -18.8% | +3.5% | Everest pairs strong earnings with heavier reserve protection |
Latest beats and misses
Who reports nextBeat on EPS
- WYFY2026 Q3 · October 29, 2026+128.3% EPS+3.0% move
- LNTFY2026 Q3 · October 29, 2026+16.0% EPS+1.4% move
- MTZFY2026 Q3 · October 29, 2026+0.3% EPS+0.8% move
- ERIEFY2026 Q3 · October 29, 2026+2.1% EPS+5.3% move
- IRFY2026 Q3 · October 29, 2026+18.5% EPS+0.2% move
- VLTOFY2026 Q3 · October 29, 2026+8.3% EPS+9.8% move
Missed on EPS
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
- AMZNFY2026 Q3 · October 29, 2026-4.1% EPS-1.6% move
- SYKFY2026 Q3 · October 29, 2026-0.8% EPS-5.0% move
- DLR-PJFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLRFY2026 Q3 · October 29, 2026-8.4% EPS-3.0% move
Get the AJG recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-30T14:17:46.071602+00:00
- FN2 earnings calendar · 2026-10-30T01:23:13.979536+00:00
- Polygon adjusted daily market bars · 2026-10-30T21:10:42.757885+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-30T21:10:42.755195+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-30. For educational purposes only; not investment advice.